Looking for a specific product?

Make a search for products & suppliers, articles & news.

Bionor Pharma's "Kick, Kill & Boost" Strategy Advances

Bionor Pharma ASA (OSE: BIONOR) announces that the Company has chosen romidepsin for the planned combination study with Vacc-4x, after considering various HDAC inhibitors (HDACi). Romidepsin is marketed in the US as Istodax® by Celgene Corporation Inc. 

The "Kick, Kill" study is planned to be conducted by the HIV research team at
Aarhus University Hospital, led by Prof. Lars Østergaard. Prof.  Østergaard
presented the background and expectations of the study at Bionor Pharma's
Capital Markets Day in June. 

 

To read more, please visit the Bionor Pharma website.

Associated companies:


Related news

Latest news

Vestdavit agrees dive boat cooperation with Hukkelberg

Opportunities in the offshore market are resurfacing after a long dry spell,

PLAR-4000 plays role in NZ seamanship excellence

The relationship between Vestdavit and Australian-headquartered Antelope Engineering extends back to 2000,

To meet the special duties envisaged,

The PL-3600R davit is equipped with shock absorbers,

Olympic Commander keeps Vestdavit alongside for Med rescue mission

To meet the special duties envisaged,

New After Sales Director on-board

Henric will take responsibility for building up strong,

MAINTENANCE CONTRACT WITH STATOIL TJELDBERGODDEN

Beerenberg has entered into a 7-year contract for ISO and other supporting services at Statoil’s Tjeldbergodden facilities. The contract is running from 1 January 2018.

DNV GL: Standardisation can help enable the digital transformation of shipping

DNV GL’s new position paper focuses on the collection of ship sensor data, 

Industry's preferred pipeline standard gets update by DNV GL

A number of requirements related to linepipe fabrication,

Servogear Hybrid CPP for the World’s First Hybrid Catamarans in Commercial Traffic

Norled AS is one of Norway’s largest ferry and express boat operators.